few weeks ago, a group of Democrats in both houses of Congress introduced the Improving Access to Affordable Prescription Drugs Act, a 129-page bill designed to lower drug prices while increasing innovation and cracking down on pharmaceutical company abuses (my thoughts on the bill are here).

There’s one provision that hasn’t gotten enough attention: the creation of a prize fund for new antibiotics.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Interesting article, thanks. With regard to the two points you highlight at the end, conditioning the prize on (1) making the product available at a low price, and (2) waiving IPRs (and other forms of exclusivity), readers may wonder why the second is necessary if the first is in effect. That is, one might ask, “if the winner of the prize can’t set a high price, why should I care any more if she still has a patent?” It would make this essay more useful if you were to explain that too. (To be clear, I think there’s a good answer to the question, I just wish it were included here, as it may not be obvious to many readers).

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.